The extended cash runway into 2029 reduces near-term dilution risk, supporting clinical development without immediate need for capital raises. Traders should monitor final Phase 2 data for NUC-7738 in 2026 as a key catalyst; positive results could support a registrational pathway in a high-unmet-need population.
Price Chart
Executive Summary
NuCana reported financial results for Q4 and full-year 2025, showing increased net losses but a strengthened cash position of £24.3 million ($30.6M), which the company expects to fund operations into 2029. The update highlighted clinical progress with NUC-7738 in melanoma, including partial responses in PD-1 resistant patients, with final Phase 2 data expected in 2026.
Key Financial Metrics
Key Facts
- NuCana reported a net loss of £29.4M for 2025 vs. £19.0M in 2024, driven by non-cash warrant revaluation and higher share-based payments.
- Cash and cash equivalents increased to £24.3M ($30.6M) at year-end 2025 from £6.7M in 2024, after raising £28.6M in gross proceeds from financing and warrant exercises.
- Company eliminated all remaining Series A Warrants by paying $3.6M, removing overhang from prior financing.
- NUC-7738 showed clinical activity in PD-1 resistant melanoma with one confirmed partial response and stable disease in multiple patients.
- Final data from Phase 2 NuTide:701 expansion study expected in 2026; FDA regulatory guidance anticipated for potential registrational pathway.
- Cash runway now extends into 2029, a significant extension from prior expectations.
Financial Impact
Net loss widened to £29.4M in 2025 from £19.0M in 2024, but cash position improved by £17.6M net due to financing activities.
Risk Factors
- Clinical development risk: NUC-7738 remains in mid-stage trials with no guarantee of success in later studies.
- Dilution history: Despite current runway, prior financings and warrant issuances indicate a history of shareholder dilution.
- Revenue-less biotech: No near-term revenue potential; valuation is entirely based on clinical outcomes.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3259416 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 30, 2026 27d ago | 6-K | $1.35 | awaiting T+60 | — | $1.10 (−18.52%) |
Jun 8, 2026 20w ago | 6-K | $2.05 $1.38 | ▼ −32.68% | ▼ −35.73% | $1.10 (−46.34%) |
Jun 1, 2026 21w ago | 6-K | $2.17 $1.47 | ▼ −32.26% | ▼ −33.49% | $1.10 (−49.31%) |
May 14, 2026 23w ago | 6-K | $2.18 $1.44 | ▼ −33.95% | ▼ −38.46% | $1.10 (−49.54%) |
May 6, 2026 24w ago | 6-K | $2.09 $1.35 | ▲ +35.41% | ▲ +39.24% | $1.10 (+47.37%) |
Mar 19, 2026 31w ago | Press Release | $1.65 $1.92 | ▲ +16.36% | ▲ +1.94% | $1.10 (−33.33%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers